A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis
Novartis
Vir Biotechnology, Inc.
Merck Sharp & Dohme LLC
MacroGenics
Merck Sharp & Dohme LLC
Janssen Research & Development, LLC
Aragon Pharmaceuticals, Inc.
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Celcuity Inc
Janssen Research & Development, LLC
T.O.A.D. Oncology SA
Pfizer
MacroGenics
Clarity Pharmaceuticals Ltd
MacroGenics
Bristol-Myers Squibb
Janux Therapeutics
Celgene
Nuvation Bio Inc.
MacroGenics
Arcus Biosciences, Inc.
Boehringer Ingelheim
Bayer
Bristol-Myers Squibb
Novartis
Endocyte
Poseida Therapeutics, Inc.
Janssen Research & Development, LLC
Lantheus Medical Imaging
Pfizer
Hoffmann-La Roche
Veru Inc.
Hoffmann-La Roche
SpectronRX
Bayer
Nuvation Bio Inc.
Nuvation Bio Inc.
Janssen Research & Development, LLC
Bayer
Bayer
Ipsen
Bayer
Janssen Pharmaceutical K.K.
Bayer
Bayer
Janssen Research & Development, LLC